Partnered Compounds
| Compound | Principal Target | Partner | Stage of Development |
|---|---|---|---|
Foretinib (GSK136089, XL880) |
VEGFR2, MET |
GlaxoSmithKline |
Phase 2
|
SAR245408 (XL147) |
PI3K |
Sanofi |
Phase 2
|
CS-3150 (XL550) |
MR |
Daiichi-Sankyo |
Phase 2
|
SAR245409 (XL765) |
PI3K, mTOR |
Sanofi |
Phase 1b/2
|
BMS-852927 (XL041) |
LXR |
Bristol-Myers Squibb |
Phase 1
|
BMS-933923 (XL139) |
Hedgehog |
Bristol-Myers Squibb |
Phase 1b
|
PI3K-δ (XL499) Inhibitor Program |
PI3K-δ |
Merck |
Preclinical
|
TGR5 (XL475) Agonist Program |
TGR5 agonists |
Bristol-Myers Squibb |
Preclinical
|
ROR Antagonists |
ROR antagonists |
Bristol-Myers Squibb |
Preclinical
|